experience, including his service at Pfizer Inc., one of the worlds largest pharmaceutical companies, in addition to his experience on several boards and involvement in the biotechnology
industry through his position as a Senior Partner and member of the Board of Directors at PureTech Health.
Cameron Geoffrey McDonough,
M.D.
Dr. McDonough has served as a member of our Board of Directors since September 2015. Since 2018, Dr. McDonough has served as the President, Chief Executive Officer and member of the Board of Directors of Generation Bio
Corporation, a biotechnology company developing a break through class of genetic medicines to enable a new generation of people unaffected by inherited disease. From 2011 to 2017, he served as President and Chief Executive Officer of Swedish Orphan
Biovitrum AB, or Sobi, a Swedish pharmaceutical company. Prior to joining Sobi, Dr. McDonough held several senior leadership positions at Genzyme Corporation, a biotechnology company, from 2002 to 2011, including Senior Vice President and
General Manager, Personalized Genetic Health, Senior Vice President, Lysosomal Storage Disease Therapeutics and most recently, as President of Europe, Middle East and Africa. Prior to joining Genzyme, Dr. McDonough was a practicing internist
and pediatrician. He currently serves on the Board of Directors of Surface Oncology. Dr. McDonough received a B.A. and a B.Sc. from the University of North Carolina at Chapel Hill and an M.D. from Harvard Medical School.
Dr. McDonoughs qualifications to sit on our Board of Directors include his valuable experience as an M.D. and the CEO of a rare disease company, Sobi, as well as his prior experience at Genzyme, one of the worlds largest
biopharmaceutical companies, in addition to his position as a chief executive officer and member of the Board of Directors of publicly traded companies.
Robert J. Perez.
Mr. Perez has served as a member of our Board of Directors since September 2015. He has served as an Operating
Partner at General Atlantic since 2019. Mr. Perez was previously the Founder and Managing Partner of Vineyard Sound Advisors, a biopharmaceutical advisory firm, since 2015. He is the former Chief Executive Officer of Cubist Pharmaceuticals,
Inc., a public pharmaceutical development company, which was acquired by Merck in 2015. He joined Cubist in 2003 as Senior Vice President, Sales and Marketing, and led the launch of Cubicin® (daptomycin for injection). He served as Executive
Vice President and Chief Operating Officer from 2007 to 2012 and President and Chief Operating Officer from 2012 to 2014. Prior to joining Cubist, he served as Vice President of Biogen, Inc.s CNS business unit from 2001 to 2003, where he was
responsible for commercial leadership of an $800 million neurology business unit, and from 1995 to 2001 he held positions of increasing responsibility within Biogens CNS commercial organization. From 1987 to 1995, Mr. Perez held
various sales and marketing positions at Zeneca Pharmaceuticals. Mr. Perez also currently serves as a member of the Board of Directors of public companies Unum Therapeutics Inc., AMAG Pharmaceuticals, Inc., and Spark Therapeutics, Inc. and sits
on the Board of several private companies in the biotechnology industry. Mr. Perez previously served on the board of directors of Cidara Therapeutics, Inc. until March 2018. Mr. Perez is the Founder and Chairman of Life Sciences Cares
since 2016, and has also been a member of the Board of Trustees at The Dana Farber Cancer Institute, Inc. since 2013. Mr. Perez received a B.S. in business from California State University, Los Angeles and an M.B.A. from the Anderson Graduate
School of Management at the University of California, Los Angeles. Mr. Perezs qualifications to sit on our Board of Directors include his valuable pharmaceutical experience, including his service at Cubist Pharmaceuticals, Inc., a
commercial stage biotechnology company, in addition to his experience at Biogen, Inc., and his experience as a director in many growth companies in the biotechnology sector.
Frank E. Thomas
. Mr. Thomas has served as a member of our Board of Directors since June 2014. Mr. Thomas has been the Chief
Financial Officer and Chief Business Officer of Orchard Therapeutics since 2018, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies. Previously, Mr. Thomas served as
President and Chief Operating Officer of AMAG Pharmaceuticals, Inc., a publicly traded, specialty pharmaceutical company, from 2015 to 2017, and previously served as AMAGs Executive Vice President and Chief Operating Officer from 2012 through
2015 and as Executive Vice President, Chief Financial Officer and Treasurer from 2011 through 2012. Prior to joining AMAG, he served as Senior Vice President, Chief Operating Officer and Chief Financial Officer for Molecular Biometrics, Inc., a
commercial stage medical diagnostics company, from 2008 to 2011. Prior to Molecular Biometrics, Mr. Thomas spent four years at Critical Therapeutics, Inc., a public biopharmaceutical company,
7